PARSIPPANY, N.J.— Zoetis Inc. has announced the addition of Ester Banque as executive vice president and president, U.S. operations, for the company. Banque is a global senior executive with more than 30 years of experience in health sciences with top tier pharmaceutical companies. Banque will be a member of the Zoetis executive team and report to Zoetis CEO Kristin Peck.
“We are excited to welcome Ester Banque to lead our U.S. business after a thoughtful and extensive search process,” Peck said. “We were impressed by Ester’s diverse, global experience, leadership of high performing teams, and above-market growth achievements. She is a passionate, purpose-driven leader who brings diverse experience and an impressive track record of driving results, which will promote Zoetis’ long-term sustainable growth.”
In this role, Banque will have responsibility for the company’s U.S. commercial operations, continuing to broaden and expand the company’s key franchises and shape the market for future innovation, providing exceptional experiences for companion animal and livestock customers, the company said.
“I am proud to join Zoetis and be part of an organization that is built on the foundation of a purpose-driven culture, powered by an innovative, robust pipeline and high-performing teams,” Banque said. “This new challenge will allow me to further expand my commitment to healthcare, and advance Zoetis’ purpose ‘to nurture our world and humankind by advancing care for animals. I am looking forward to building on Zoetis’ leadership in animal health and capitalizing on opportunities to make a positive impact on our customers, colleagues and communities.”
In connection with Banque’s appointment, William (Chip) Dorsey, interim head of U.S. operations since February 2023, will continue in his finance leadership role and be a resource to Banque as she onboards.
“On behalf of the Zoetis Executive Team, I also want to thank Chip for his leadership over the past five months,” Peck said.
Most recently, Banque served as senior vice president and general manager of Bristol Myers-Squibb’s U.S. Hematology & Cell Therapy Business.
